1. Home
  2. GTBP vs ORIS Comparison

GTBP vs ORIS Comparison

Compare GTBP & ORIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GTBP
  • ORIS
  • Stock Information
  • Founded
  • GTBP 1965
  • ORIS 2014
  • Country
  • GTBP United States
  • ORIS China
  • Employees
  • GTBP N/A
  • ORIS N/A
  • Industry
  • GTBP Biotechnology: Pharmaceutical Preparations
  • ORIS Farming/Seeds/Milling
  • Sector
  • GTBP Health Care
  • ORIS Consumer Staples
  • Exchange
  • GTBP Nasdaq
  • ORIS Nasdaq
  • Market Cap
  • GTBP 5.5M
  • ORIS 5.3M
  • IPO Year
  • GTBP N/A
  • ORIS 2024
  • Fundamental
  • Price
  • GTBP $0.95
  • ORIS $0.11
  • Analyst Decision
  • GTBP Strong Buy
  • ORIS
  • Analyst Count
  • GTBP 1
  • ORIS 0
  • Target Price
  • GTBP $11.00
  • ORIS N/A
  • AVG Volume (30 Days)
  • GTBP 292.5K
  • ORIS 63.9M
  • Earning Date
  • GTBP 08-14-2025
  • ORIS 01-01-0001
  • Dividend Yield
  • GTBP N/A
  • ORIS N/A
  • EPS Growth
  • GTBP N/A
  • ORIS N/A
  • EPS
  • GTBP N/A
  • ORIS 0.17
  • Revenue
  • GTBP N/A
  • ORIS $15,014,000.00
  • Revenue This Year
  • GTBP N/A
  • ORIS N/A
  • Revenue Next Year
  • GTBP N/A
  • ORIS N/A
  • P/E Ratio
  • GTBP N/A
  • ORIS $0.68
  • Revenue Growth
  • GTBP N/A
  • ORIS N/A
  • 52 Week Low
  • GTBP $0.88
  • ORIS $0.08
  • 52 Week High
  • GTBP $4.10
  • ORIS $56.01
  • Technical
  • Relative Strength Index (RSI)
  • GTBP 26.68
  • ORIS 33.79
  • Support Level
  • GTBP $0.88
  • ORIS $0.11
  • Resistance Level
  • GTBP $0.99
  • ORIS $0.12
  • Average True Range (ATR)
  • GTBP 0.10
  • ORIS 0.01
  • MACD
  • GTBP 0.01
  • ORIS 0.02
  • Stochastic Oscillator
  • GTBP 9.92
  • ORIS 47.00

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

About ORIS Oriental Rise Holdings Limited Ordinary Shares

Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).

Share on Social Networks: